Fig. 2From: Safety and efficacy of the choline analogue SAR97276 for malaria treatment: results of two phase 2, open-label, multicenter trials in African patientsStudy flow and inclusion of study participants (N) to SAR97276A allocation groups (Study 1). Group 1A: 1 day IM to adults; Group 1B: 3 days IM to adults; Group 1C: 1 day IV to adults; Group 1D: 3 days IM to childrenBack to article page